StockData
NRC Health logo

NRC Health (NRC) company profile

NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/3078% above fair value
$25.89−0.44 (-1.69%)

Close on Nov 17, 2026Market cap $572.57MP/E –Yield 2.01%

About NRC Health

Services-Commercial Physical & Biological Research, SIC 8731

National Research Corporation, doing business as NRC Health, provides experience management solutions, data analytics, and actionable insights for the healthcare sector. The company's digital offerings span four primary categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. In addition, its Governance Solutions, operating as The Governance Institute, deliver advisory services, research, conferences, and publications. These solutions assist healthcare organizations in capturing constituent feedback, evaluating brand perception, engaging clinical staff, and strengthening executive governance. Customers include healthcare systems, hospital boards, executives, and physician leadership across the care continuum.

The company maintains a diversified customer base distributed across the United States. Its syndicated survey database annually measures the opinions and behaviors of approximately 300,000 healthcare consumers across the contiguous United States. National Research Corporation is incorporated in Delaware and operates its principal executive offices in Lincoln, Nebraska.

Summary of the business section of NRC Health's latest annual report, written by StockData.

Company profile

Company

Legal name
NRC Health
Founded
1981
Headquarters
Lincoln, NE
Address
1245 Q Street 68508
Phone
(402) 475-2525
Employees
357, Dec 31, 2025
Industry
Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Omaha, Nebraska

Stock & identifiers

Ticker
NRC
Former tickers
NRCI until May 4, 2018
Exchange
Nasdaq
IPO date
May 23, 2013
Shares outstanding
22M, Jul 31, 2026
Public float
$194.76M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
70487
CUSIP
637372202
ISIN
US6373722023
FIGI
BBG004K1F8W7
Share class FIGI
BBG004K1F9R1
LEI
549300FQIORB6GZCYT15
EIN
47-0634000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael D. HaysChairman, Director96,249
Trent S. GreenChief Executive Officer, Director500,000
Helen HrdyEVP & Chief Operating Officer142,646
Jason Russell RauExecutive Vice President60,000
Shane R. HarrisonEVP & Chief Financial Officer158,729
David BurikEVP, Strategic Insights100,000
Jordan Nicole FreemanChief Accounting Officer771
Andrew MonnichChief Corp. Development Off.100,000
Linda StacyInterim Principal Fin. Off.–
Parul BhandariDirector7,697
John N. NunnellyDirector40,363
Penny Ann WheelerDirector7,697
Stephen H. LockhartDirector7,697
Donald M. BerwickDirector7,697

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mr Green
$11.96M$14.79M$1.62M$47$134
FY2025
Mr Hays
$184.42K$203.34K$1.62M$47$134
FY2024
Mr Green
$0$0$1.12M$29$143
FY2024
Mr Hays
$184.86K-$43.48K$1.12M$29$143
FY2023
Mr Green
$0$0$428.16K$64$128
FY2023
Mr Hays
$195.57K$202.17K$428.16K$64$128

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Trent Green
Chief Executive Officer (2)
$697.12K$4.50M$6.76M––$6.45K$11.96M–
Shane Harrison
Chief Financial Officer (2)
$92.31K$100.00K$2.29M––$1.19K$2.48M–
Helen L. Hrdy
EVP & Chief Operating Officer
$400.00K$826.67K$1.24M––$8.18K$2.47M+60%
Andy Monnich
EVP & Chief Corporate Development Officer
$400.00K$826.67K$1.24M––$8.15K$2.47M–
Jason Rau
Executive Vice President, Sales
$362.31K–––$249.52K$7.31K$619.13K–
Michael D. Hays
Chair; Former Chief Executive Officer, President (2)
$127.40K––$54.55K–$2.46K$184.42K-0%
Linda Stacy
Former Interim Principal Financial Officer (2)
$12.50K––––$47.50K$60.00K-76%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed a total of 357 associates.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 27, 2026Name changeName changed from NATIONAL RESEARCH CORP to NRC Health
Apr 20, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 17, 2018DelistingNotice of delisting from exchange (Form 25)
Apr 17, 2018DeregistrationTermination of SEC registration (Form 15)
May 16, 2013ListingRegistration of securities on an exchange (Form 8-A)
Aug 9, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 29, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 31, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?